Please assess the completion status of the following clinical trial:

Trial Title: Natural Killer(NK) Cell Therapy for AML Minimal Residual Disease

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Key Inclusion Criteria:~* Provision of signed and dated informed consent form(ICF)~* ≥18 years old~* Subject diagnosed of AML MRD.~* Eastern Cooperative Oncology Group (ECOG) performance status ≤1~* Adequate organ function as defined in the protocol~* Donor specific antibody (DSA) to QN-030a: MFI ≤ 2000~Key Exclusion Criteria:~* Allergic to drug used in this study~* Accept other anti-tumor drug within 2 weeks of day 0 (first QN-030a dose infusion)~* Prior allogeneic hematopoietic stem cell transplant (HSCT) within 6 months of Day 0, received systemic immunosuppressive therapy within 7 days of Day 0, or likely to require systemic immunosuppressive therapy~* Acute Promyelocytic Leukemia (APL)~* Active central nervous system Leukemia.~* Uncontrolled, active clinically significant infection~* Clinically significant cardiovascular disease as defined in the protocol~* History of central nervous system (CNS) disease such as stroke, epilepsy.~* Females are pregnant or lactating~* Known HIV infection, active Hepatitis B (HBV) or Hepatitis C (HCV) infection~* Investigator-assessed presence of any medical or social issues that are likely to interfere with study conduct or may cause increased risk to subject

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- QN-030a (Type: EXPERIMENTAL): QN-030a in Adult subjects with MRD

Based on this trial design, predict the completion outcome and termination type (if applicable).